Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience.
Mert Tokcan, Franciska Diana Wolter, Mathias Hohl et al.
✦ AI-curated · Sources linked
Case in brief
A patient with recurrent uncontrolled hypertension and cardiometabolic comorbidity despite prior renal denervation and limited medical treatment options underwent ultrasound common hepatic artery denervation. The procedure was completed without intraprocedural complications, and follow-up revealed no hepatobiliary, pancreatic, or renal safety signal. Mean 24-hour blood pressure fell from 179/88 mmHg at baseline to 139/83 mmHg at 6 months without intensification of antihypertensive therapy. Hepatic fat fraction, HbA1c, insulin requirement, and body weight also declined, while patient-reported outcomes improved.
What made this case unusual
The case describes first-in-human common hepatic artery denervation for persistent hypertension, with concurrent changes in blood pressure and several cardiometabolic measures after prior renal denervation.
Diagnostic / clinical pearl
In this single case, hepatic artery denervation was technically feasible without an observed hepatobiliary, pancreatic, or renal safety signal; the reported hemodynamic and metabolic changes warrant prospective evaluation rather than establishing efficacy.